These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

345 related items for PubMed ID: 23232273

  • 1. (4S)-4-(3-18F-fluoropropyl)-L-glutamate for imaging of xC transporter activity in hepatocellular carcinoma using PET: preclinical and exploratory clinical studies.
    Baek S, Mueller A, Lim YS, Lee HC, Lee YJ, Gong G, Kim JS, Ryu JS, Oh SJ, Lee SJ, Bacher-Stier C, Fels L, Koglin N, Schatz CA, Dinkelborg LM, Moon DH.
    J Nucl Med; 2013 Jan; 54(1):117-23. PubMed ID: 23232273
    [Abstract] [Full Text] [Related]

  • 2. Exploratory clinical trial of (4S)-4-(3-[18F]fluoropropyl)-L-glutamate for imaging xC- transporter using positron emission tomography in patients with non-small cell lung or breast cancer.
    Baek S, Choi CM, Ahn SH, Lee JW, Gong G, Ryu JS, Oh SJ, Bacher-Stier C, Fels L, Koglin N, Hultsch C, Schatz CA, Dinkelborg LM, Mittra ES, Gambhir SS, Moon DH.
    Clin Cancer Res; 2012 Oct 01; 18(19):5427-37. PubMed ID: 22893629
    [Abstract] [Full Text] [Related]

  • 3. Utility of [18F]FSPG PET to Image Hepatocellular Carcinoma: First Clinical Evaluation in a US Population.
    Kavanaugh G, Williams J, Morris AS, Nickels ML, Walker R, Koglin N, Stephens AW, Washington MK, Geevarghese SK, Liu Q, Ayers D, Shyr Y, Manning HC.
    Mol Imaging Biol; 2016 Dec 01; 18(6):924-934. PubMed ID: 27677886
    [Abstract] [Full Text] [Related]

  • 4. Exploratory Clinical Investigation of (4S)-4-(3-18F-Fluoropropyl)-L-Glutamate PET of Inflammatory and Infectious Lesions.
    Chae SY, Choi CM, Shim TS, Park Y, Park CS, Lee HS, Lee SJ, Oh SJ, Kim SY, Baek S, Koglin N, Stephens AW, Dinkelborg LM, Moon DH.
    J Nucl Med; 2016 Jan 01; 57(1):67-9. PubMed ID: 26471694
    [Abstract] [Full Text] [Related]

  • 5. Specific PET imaging of xC- transporter activity using a ¹⁸F-labeled glutamate derivative reveals a dominant pathway in tumor metabolism.
    Koglin N, Mueller A, Berndt M, Schmitt-Willich H, Toschi L, Stephens AW, Gekeler V, Friebe M, Dinkelborg LM.
    Clin Cancer Res; 2011 Sep 15; 17(18):6000-11. PubMed ID: 21750203
    [Abstract] [Full Text] [Related]

  • 6. Pilot Preclinical and Clinical Evaluation of (4S)-4-(3-[18F]Fluoropropyl)-L-Glutamate (18F-FSPG) for PET/CT Imaging of Intracranial Malignancies.
    Mittra ES, Koglin N, Mosci C, Kumar M, Hoehne A, Keu KV, Iagaru AH, Mueller A, Berndt M, Bullich S, Friebe M, Schmitt-Willich H, Gekeler V, Fels LM, Bacher-Stier C, Moon DH, Chin FT, Stephens AW, Dinkelborg LM, Gambhir SS.
    PLoS One; 2016 Sep 15; 11(2):e0148628. PubMed ID: 26890637
    [Abstract] [Full Text] [Related]

  • 7. Prospective comparison of (4S)-4-(3-18F-fluoropropyl)-L-glutamate versus 18F-fluorodeoxyglucose PET/CT for detecting metastases from pancreatic ductal adenocarcinoma: a proof-of-concept study.
    Cheng MF, Huang YY, Ho BY, Kuo TC, Hsin LW, Shiue CY, Kuo HC, Jeng YM, Yen RF, Tien YW.
    Eur J Nucl Med Mol Imaging; 2019 Apr 15; 46(4):810-820. PubMed ID: 30635754
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. PET Imaging of L-Type Amino Acid Transporter (LAT1) and Cystine-Glutamate Antiporter (xc-) with [18F]FDOPA and [18F]FSPG in Breast Cancer Models.
    Krys D, Mattingly S, Glubrecht D, Wuest M, Wuest F.
    Mol Imaging Biol; 2020 Dec 15; 22(6):1562-1571. PubMed ID: 32789819
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma.
    Trojan J, Schroeder O, Raedle J, Baum RP, Herrmann G, Jacobi V, Zeuzem S.
    Am J Gastroenterol; 1999 Nov 15; 94(11):3314-9. PubMed ID: 10566736
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Imaging of proliferation in hepatocellular carcinoma with the in vivo marker 18F-fluorothymidine.
    Eckel F, Herrmann K, Schmidt S, Hillerer C, Wieder HA, Krause BJ, Schuster T, Langer R, Wester HJ, Schmid RM, Schwaiger M, Buck AK.
    J Nucl Med; 2009 Sep 15; 50(9):1441-7. PubMed ID: 19690030
    [Abstract] [Full Text] [Related]

  • 17. Assessment of [(18)F]-fluoroacetate PET/CT as a tumor-imaging modality: preclinical study in healthy volunteers and clinical evaluation in patients with liver tumor.
    Takemoto K, Hatano E, Nishii R, Kagawa S, Kishibe Y, Takahashi M, Yamauchi H, Matsumura K, Zaima M, Toriguchi K, Tanabe K, Kitamura K, Seo S, Taura K, Endo K, Uemoto S, Higashi T.
    Ann Nucl Med; 2014 May 15; 28(4):371-80. PubMed ID: 24599824
    [Abstract] [Full Text] [Related]

  • 18. Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma.
    Ho CL, Chen S, Yeung DW, Cheng TK.
    J Nucl Med; 2007 Jun 15; 48(6):902-9. PubMed ID: 17504862
    [Abstract] [Full Text] [Related]

  • 19. 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses.
    Ho CL, Yu SC, Yeung DW.
    J Nucl Med; 2003 Feb 15; 44(2):213-21. PubMed ID: 12571212
    [Abstract] [Full Text] [Related]

  • 20. Use of (18)F-FDG PET to predict tumor progression and survival in patients with intermediate hepatocellular carcinoma treated by transarterial chemoembolization.
    Kim MJ, Kim YS, Cho YH, Jang HY, Song JY, Lee SH, Jeong SW, Kim SG, Jang JY, Kim HS, Kim BS, Lee WH, Park JM, Lee JM, Lee MH, Choi DL.
    Korean J Intern Med; 2015 May 15; 30(3):308-15. PubMed ID: 25995661
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.